The Vanishing Premium: How Bitcoin’s Luster Faded for Corporate Treasuries

The investment thesis of loading corporate balance sheets with Bitcoin has lost its appeal. Medical device firm Semler Scientific, which garnered significant attention for its aggressive cryptocurrency acquisitions, now serves as a prime example of a sharp reversal in market sentiment. The speculative premium that investors were previously willing to pay for this strategy has all but evaporated.

A Market Reassessment

Recent analysis from Galaxy Research highlights a fundamental shift. For months, the market treated companies holding substantial Bitcoin reserves as leveraged bets on the digital asset itself. This drove share prices well above the underlying net asset value (NAV) of the Bitcoin held. That dynamic has now inverted. The equity premium for firms following the “Digital Asset Treasury” (DAT) model, which includes Semler Scientific, has collapsed to nearly zero or even turned into a discount to NAV. The market is fundamentally re-rating this strategy, stripping away the speculative support that once buoyed these stocks.

Dual Pressure from a Crypto Correction

Semler Scientific’s valuation is under direct pressure from Bitcoin’s recent downturn. The cryptocurrency has retreated from its October highs near $126,000 to a current trading range of approximately $89,000 to $92,000. This creates a dual headwind: not only does the value of the asset on the balance sheet decline, but the market is also no longer willing to pay a premium on that shrinking value. This trend is sector-wide. Other companies, such as Metaplanet, are reporting substantial unrealized losses from their Bitcoin holdings.

Should investors sell immediately? Or is it worth buying Semler Scientific?

In the current environment, the DAT approach chosen by Semler Scientific for diversification is providing neither a defensive hedge nor the hoped-for leveraged upside. The company’s shares, after a pronounced decline in recent weeks and months, are trading at €16.10, a significant distance from their 52-week high. The stock’s close correlation with Bitcoin’s price is currently overshadowing the valuation of its core medical technology operations.

Outlook Tied to Cryptocurrency Stability

Current sentiment suggests the era of easy premiums for corporate Bitcoin treasuries has ended, at least for now. Market strategists interpret the collapse of the NAV premium as a sign that institutional investors are de-risking. Until the Bitcoin market establishes a new, stable foundation, Semler Scientific’s stock remains exposed to the downside risks of its treasury strategy. Its near-term trajectory is now heavily dependent on a stabilization of the broader cryptocurrency market.